{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T12:31:29Z","timestamp":1789993889573,"version":"4.0.1"},"reference-count":49,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2018,1,2]],"date-time":"2018-01-02T00:00:00Z","timestamp":1514851200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Ministry of Education, Culture, Sports, Science and Technology for the Coordination, Support and Training Program for Translational Research","award":["08061012"],"award-info":[{"award-number":["08061012"]}]},{"name":"This study was financially supported by Grant-in-Aid for Scientific Research of Japan Society for the Promotion of Science","award":["YS24790708, YS22790651"],"award-info":[{"award-number":["YS24790708, YS22790651"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0187878","type":"journal-article","created":{"date-parts":[[2018,1,2]],"date-time":"2018-01-02T14:21:15Z","timestamp":1514902875000},"page":"e0187878","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":18,"title":["A phase I clinical trial of RNF43 peptide-related immune cell therapy combined with low-dose cyclophosphamide in patients with advanced solid tumors"],"prefix":"10.1371","volume":"13","author":[{"given":"Yasuki","family":"Hijikata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiko","family":"Okazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mutsunori","family":"Murahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunari","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junji","family":"Kishimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoichi","family":"Nakanishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinao","family":"Oda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3335-6188","authenticated-orcid":true,"given":"Kenzaburo","family":"Tani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2018,1,2]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1001\/jama.1994.03510360033032","article-title":"Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2","volume":"271","author":"SA Rosenberg","year":"1994","journal-title":"JAMA"},{"key":"ref2","article-title":"Current methods of epitope identification for cancer vaccine design","volume":"15","author":"GA Cherryholmes","year":"2015","journal-title":"Vaccine"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1470-2045(13)70585-0","article-title":"Clinical use of dendritic cells for cancer therapy","volume":"15","author":"S Anguille","year":"2014","journal-title":"Lancet Oncol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"3384","DOI":"10.1158\/1078-0432.CCR-14-2675","article-title":"The evolution of t-cell therapies for solid malignancies","volume":"21","author":"K Fousek","year":"2015","journal-title":"Clin Cancer Res"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1056\/NEJMoa1012863","article-title":"gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma","volume":"364","author":"D.J. Schwartzentruber","year":"2011","journal-title":"N. Engl. J. Med"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"5300","DOI":"10.1158\/1078-0432.CCR-13-0143","article-title":"CTLA-4 and PD-1\/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients","volume":"19","author":"PA Ott","year":"2013","journal-title":"Clin Cancer Res"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"63","author":"PW Kantoff","year":"2010","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/nature.2015.16990","article-title":"Therapeutic cancer vaccine survives biotech bust","volume":"519","author":"H Ledford","year":"2015","journal-title":"Nature"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1093\/annonc\/mdj138","article-title":"Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG","volume":"17","author":"D Schadendorf","year":"2006","journal-title":"Ann Oncol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1158\/0008-5472.CAN-11-3912","article-title":"Regulatory T-cell modulation using cyclophosphamide in vaccine approaches: a current perspective","volume":"72","author":"DT Le","year":"2012","journal-title":"Cancer Res"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s00262-009-0734-3","article-title":"Cyclophosphamide resets dendritic cell homeostasis and enhances anti- tumor immunity through effects that extend beyond regulatory T cell elimination","volume":"59","author":"V Radojcic","year":"2010","journal-title":"Cancer Immunol Immunother"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"6783","DOI":"10.1158\/0008-5472.CAN-04-1621","article-title":"Dendritic cells strongly boost the antitumor activity of adoptively transferred T cells in vivo","volume":"64","author":"Y Lou","year":"2004","journal-title":"Cancer Res"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"16168","DOI":"10.1073\/pnas.242600099","article-title":"Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells","volume":"99","author":"C Yee","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1097\/00008390-200310000-00011","article-title":"Results of a phase 1 clinical study using autologous tumor lysate-pulsed monocyte-derived mature dendritic cell vaccinations for stage IV malignant melanoma patients combined with low dose interleukin-2","volume":"13","author":"H Nakayam","year":"2003","journal-title":"Melanoma Res"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.clim.2016.03.015","article-title":"Phase I clinical trial of a five-peptide cancer vaccine combined with cyclophosphamide in advanced solid tumors","volume":"166","author":"M Murahashi","year":"2016","journal-title":"Clin Immunol"},{"key":"ref16","first-page":"1343","article-title":"Nakamura Y: A novel oncoprotein RNF43 functions in an autocrine manner in colorectal cancer","volume":"25","author":"R Yagyu","year":"2004","journal-title":"Int J Oncol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/j.yexcr.2008.01.013","article-title":"A cancer-associated RING finger protein, RNF43, is a ubiquitin ligase that interacts with a nuclear protein, HAP95","volume":"314","author":"T Sugiura","year":"2008","journal-title":"Exp Cell Res"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"8577","DOI":"10.1158\/1078-0432.CCR-04-0104","article-title":"Ring finger protein 43 as a new target for cancer immunotherapy","volume":"10","author":"N Uchida","year":"2004","journal-title":"Clin Cancer Res"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1158\/1535-7163.MCT-12-0672","article-title":"Reversing effect of ring finger protein 43 inhibition on malignant phenotypes of human hepatocellular carcinoma","volume":"1","author":"C Xing","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nri1001","article-title":"Interleulin-12 and the regulation of innate resistance and adaptive immunity","volume":"3","author":"G. Trinchieri","year":"2003","journal-title":"Nat Rev Immunol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.immuni.2008.11.002","article-title":"Surh Jonathan Sprent. Homeostasis of na\u00efve and memory T cells","volume":"29","author":"D Charles","year":"2008","journal-title":"Immunity"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1158\/1078-0432.CCR-0095-03","article-title":"gp100(209\u20142M) peptide immunization of human lymphocyte antigen-A2 + stage I-III melanoma patients induces significant increase in antigen-specific effector and long-term memory CD8+ T cells","volume":"10","author":"EB Walker","year":"2004","journal-title":"Clin Cancer Res"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jim.2007.03.002","article-title":"Optimization and validation of an 8-color intracellular cytokine staining (ICS) assay to quantify antigen-specific T cells induced by vaccination","volume":"323","author":"H Horton","year":"2007","journal-title":"J Immunol Methods"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"5270","DOI":"10.1158\/1078-0432.CCR-08-0022","article-title":"Phenotype and functional characterization of long-term gp100-specific memory CD8+ T cells in disease-free melanoma patients before and after boosting immunization","volume":"14","author":"EB Walker","year":"2008","journal-title":"Clin Cancer Res"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1126\/science.1129139","article-title":"Type, density, and location of immune cells within human colorectal tumors predict clinical outcome","volume":"313","author":"J Galon","year":"2006","journal-title":"Science"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1038\/ng.3127","article-title":"<italic>RNF43<\/italic> is frequently mutated in colorectal and endometrial cancers","volume":"46","author":"M Giannakis","year":"2014","journal-title":"Nat Genet"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1097\/CJI.0b013e31816cabbb","article-title":"Nonmyeloablative chemotherapy followed by T-cell adoptive transfer and dendritic cell-based vaccination results in rejection of established melanoma","volume":"31","author":"N Koike","year":"2008","journal-title":"J Immunother"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"6783","DOI":"10.1158\/0008-5472.CAN-04-1621","article-title":"Dendritic cells strongly boost the antitumor activity of adoptively transferred T cells in vivo","volume":"64","author":"Y Lou","year":"2004","journal-title":"Cancer Res"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"7322","DOI":"10.1016\/j.vaccine.2007.08.037","article-title":"The optimal interval for dendritic cell vaccination following adoptive T cell transfer is important for boosting potent anti-tumor immunity","volume":"25","author":"MY Park","year":"2007","journal-title":"Vaccine"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/nri1806","article-title":"Regulatory T cells, tumour immunity and immunotherapy","volume":"6","author":"Weiping Zou","year":"2006","journal-title":"Nature Reviews Immunology"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s00262-012-1322-5","article-title":"Low-dose cyclophosphamide administered as daily or single dose enhances the antitumor effects of a therapeutic HPV vaccine","volume":"62","author":"S Peng","year":"2013","journal-title":"Cancer Immunol Immunother"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"4850","DOI":"10.1158\/0008-5472.CAN-10-0283","article-title":"Selective depleteon of CD4+CD25+Foxp3+ regulatory T cells by low-dose cyclophosphamide is explained by reduced intracellular ATP levels","volume":"70","author":"J Zhao","year":"2010","journal-title":"Cancer Res"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"5060","DOI":"10.1200\/JCO.2006.07.1100","article-title":"Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma","volume":"24","author":"A Mackensen","year":"2006","journal-title":"J Clin Oncol"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s00262-007-0435-8","article-title":"Phase I\/II study of treatment with matured dendritic cells with or without low dose IL-2 in patients with disseminated melanoma","volume":"57","author":"P Hersey","year":"2008","journal-title":"Cancer Immunol Immunother"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1007\/s00262-013-1397-7","article-title":"Effects of cyclophosphamide and IL-2 on regulatory CD4+ T cell frequency and function in melanoma patients vaccinated with HLA-class I peptides: impact on the antigen-specific T cell response","volume":"62","author":"C Camisaschi","year":"2013","journal-title":"Cancer Immunol Immunother"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.4049\/jimmunol.170.4.2161","article-title":"Survival and tumor localization of adoptively transferred Melan-A-specific T cells in melanoma patients","volume":"170","author":"N Meidenbauer","year":"2003","journal-title":"J Immunol"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"4550","DOI":"10.1158\/1078-0432.CCR-11-0116","article-title":"Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy","volume":"17","author":"SA Rosenberg","year":"2011","journal-title":"Clin Cancer Res"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.it.2015.02.008","article-title":"Overcoming T cell exhaustion in infection and cancer","volume":"36","author":"KE Pauken","year":"2015","journal-title":"Trends Immunol"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1038\/bjc.1994.175","article-title":"Serum interleukin 6 and C-reactive protein levels correlate with resistance to IL-2 therapy and poor survival in melanoma patients","volume":"69","author":"E Tartour","year":"1994","journal-title":"Br J Cancer"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"6083","DOI":"10.1158\/1078-0432.CCR-11-0945","article-title":"Interleukin-6 as a therapeutic target in human ovarian cancer","volume":"17","author":"J Coward","year":"2011","journal-title":"Clin Cancer Res"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"3408","DOI":"10.4049\/jimmunol.0901751","article-title":"ATP activates regulatory T Cells in vivo during contact hypersensitivity reactions","volume":"184","author":"S Ring","year":"2010","journal-title":"J Immunol"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"21188","DOI":"10.1073\/pnas.1118046108","article-title":"Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways","volume":"108","author":"J Wu","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/nature11308","article-title":"Tumour suppressor RNF43 is a stem-cell E3 ligase that induces endocytosis of Wnt receptors","volume":"488","author":"BK Koo","year":"2012","journal-title":"Nature"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/modpathol.2014.98","article-title":"Clinicopathological significance of somatic <italic>RNF43<\/italic> mutation and aberrant expression of ring finger protein 43 in intraductal papillary mucinous neoplasms of the pancreas","volume":"28","author":"H Sakamoto","year":"2015","journal-title":"Mod Pathol"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/1479-5876-12-63","article-title":"A phase I study of combination vaccine treatment of five therapeutic epitope-peptides for metastatic colorectal cancer; safety, immunological response, and clinical out-come","volume":"12","author":"S Hazama","year":"2014","journal-title":"J Transl Med"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"951","DOI":"10.3892\/or.2013.2231","article-title":"Phase I clinical trial of a peptide vaccine combined with tegafur-uracil plus leucovorin for treatment of advanced or recurrent colorectal cancer","volume":"29","author":"N Matsushita","year":"2013","journal-title":"Oncol Rep"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3390\/cancers8060054","article-title":"Control of Wnt receptor Turnover by R-spondin-ZNR3\/RNF43 Signaling Module and Its Dysregulation in Cancer","volume":"8","author":"HX Hao","year":"2016","journal-title":"Cancers"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1126\/science.aaa8172","article-title":"The future of immune checkpoint therapy","volume":"348","author":"P Sharma","year":"2015","journal-title":"Science"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 Blockade in Tumors with Mismatch-Repair Deficiency","volume":"372","author":"DT Le","year":"2015","journal-title":"N Engl J Med"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0187878","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,24]],"date-time":"2018-10-24T00:27:14Z","timestamp":1540340834000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0187878"}},"subtitle":[],"editor":[{"given":"Takeshi","family":"Nagasaka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2018,1,2]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,1,2]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0187878","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,2]]}}}